Clinipace to Manage Phase II Trial in Kidney Disease
February 12, 2014
Applied Clinical Trials
Therapeutically-Focused Clinical Development Team Leverages Technology-Amplified dCRO Model to Streamline Efficiencies, Reduce Development Costs
Clinipace Worldwide, announced that Phosphate Therapeutics, co-owned and resourced by Shield Therapeutics (Shield), an independent specialty pharmaceutical company, has selected the company to manage its first pivotal trial in its late stage nephrology program expected to commence in 2014.
Clinipace will manage the Phase II trial of PT20, a novel iron-based phosphate binder being developed for the treatment of hyperphosphataemia related to chronic kidney disease (CKD). Hyperphosphataemia is a life-threatening complication of CKD, the incidence of which is increasing globally as obesity and diabetes levels rapidly rise. The treatment of this condition is a significant unmet medical need, which the company states provides it with a strategic opportunity for Phosphate and Clinipace to partner in research.
